Untitled

Order Your (Apixaban) Eliquis Online & Experience the Difference

APIXABAN helps to stop blood clots from forming. You need to tell your doctor or pharmacist if you are taking any other medicines. This includes any vitamins or minerals, herbal supplements or medicines you bought without a prescription from a pharmacy, supermarket or health food store. It is a good idea to carry an up-to-date list of all your medicines. Consider wearing a medical alert bracelet.

Swallow the tablet whole. You can take it with or without food. Your pharmacist can put APIXABAN in a dose administration aid, such as a Webster Pak®.

Eliquis contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

Eliquis is used in adults: -

to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.

Apixaban is a blood thinner or anticoagulant. Anticoagulants help treat and prevent blood clots.

YOU ARE TAKING APIXABAN:

To help prevent stroke because you have atrial fibrillation

To help treat the blood clot in your leg (deep vein thrombosis or DVT) and/or blood clot in your lung (Pulmonary Embolism or PE)

To help prevent DVT or PE) after hip or knee surgery

 To help prevent another DVT or PE if you already had one

YOUR DOSE OF APIXABAN IS:

Atrial fibrillation: 5 mg twice a day (2.5 mg twice a day for some people)

Prevention of DVT or PE after hip or knee replacement: 2.5 mg twice a day

Treatment of DVT or PE: 10 mg twice a day for 1 week, followed by 5 mg twice a day for at least 3 months

Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.

In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause.